A retrospective study to evaluate real world experience in treating spinal muscular atrophy (SMA) patients with dual therapy of nusinersen and AVXS-101 (zolgensma)
Latest Information Update: 20 May 2020
At a glance
- Drugs Nusinersen (Primary) ; Onasemnogene-abeparvovec (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
Most Recent Events
- 20 May 2020 New trial record
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology